Details of the Drug

General Information of Drug (ID: DMAUHQX)

Drug Name
Methdilazine
Synonyms
Disyncram; Methdilazinum; Methodilazine; Metodilazina; Tacaryl; Tacazyl; Tacryl; Methilazine hydrochloride; Methdilazine (INN); Methdilazinum [INN-Latin]; Metodilazina [INN-Spanish]; Tacaryl (TN); Methdilazine [USAN:INN:BAN]; 10-((1-Methyl-3-pyrrolidinyl)methyl)phenothiazine; 10-((1-methyl-3-pyrrolidinyl)methyl)-10H-phenothiazine; 10-[(1-Methylpyrrolidin-3-yl)methyl]phenothiazine; 10-[(1-methylpyrrolidin-3-yl)methyl]-10H-phenothiazine
Indication
Disease Entry ICD 11 Status REF
Allergic rhinitis CA08.0 Approved [1]
Angioedema 4A00.15 Approved [2]
Urticaria EB00-EB05 Approved [2]
Pruritus EC90 Investigative [2]
Therapeutic Class
Antihistamines
Affected Organisms
Humans and other mammals
ATC Code
R06AD04: Methdilazine
R06AD: Phenothiazine derivatives
R06A: ANTIHISTAMINES FOR SYSTEMIC USE
R06: ANTIHISTAMINES FOR SYSTEMIC USE
R: RESPIRATORY SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 296.4
Logarithm of the Partition Coefficient (xlogp) 5.2
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Absorption
The drug is well absorbed in the digestive tract []
Chemical Identifiers
Formula
C18H20N2S
IUPAC Name
10-[(1-methylpyrrolidin-3-yl)methyl]phenothiazine
Canonical SMILES
CN1CCC(C1)CN2C3=CC=CC=C3SC4=CC=CC=C42
InChI
InChI=1S/C18H20N2S/c1-19-11-10-14(12-19)13-20-15-6-2-4-8-17(15)21-18-9-5-3-7-16(18)20/h2-9,14H,10-13H2,1H3
InChIKey
HTMIBDQKFHUPSX-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
14677
ChEBI ID
CHEBI:6823
CAS Number
1982-37-2
UNII
4Q13LY9Z8X
DrugBank ID
DB00902
TTD ID
D0LR0R
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histamine H1 receptor (H1R) TTTIBOJ HRH1_HUMAN Antagonist [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Gene/Protein Processing [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Allergic rhinitis
ICD Disease Classification CA08.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Histamine H1 receptor (H1R) DTT HRH1 6.74E-01 0.13 0.43
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Methdilazine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Chlorpheniramine DM5URA2 Moderate Additive anticholinergic effects by the combination of Methdilazine and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [5]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Methdilazine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [6]
Coadministration of a Drug Treating the Disease Different from Methdilazine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Methdilazine and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [6]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Methdilazine and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [6]
Memantine DMD9WSC Moderate Additive anticholinergic effects by the combination of Methdilazine and Memantine. Alzheimer disease [8A20] [5]
Rivastigmine DMG629M Moderate Antagonize the effect of Methdilazine when combined with Rivastigmine. Alzheimer disease [8A20] [7]
Amyl nitrite DMJKO05 Moderate Additive hypotensive effects by the combination of Methdilazine and Amyl nitrite. Angina pectoris [BA40] [8]
Nifedipine DMSVOZT Moderate Additive hypotensive effects by the combination of Methdilazine and Nifedipine. Angina pectoris [BA40] [8]
Ephedrine DMMV0KW Moderate Antagonize the effect of Methdilazine when combined with Ephedrine. Asthma [CA23] [9]
Lisdexamfetamine DM6W8V5 Moderate Antagonize the effect of Methdilazine when combined with Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [9]
Desipramine DMT2FDC Moderate Increased plasma concentrations of Methdilazine and Desipramine due to competitive inhibition of the same metabolic pathway. Attention deficit hyperactivity disorder [6A05] [10]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Methdilazine and Cariprazine. Bipolar disorder [6A60] [5]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Methdilazine when combined with Acetylcholine. Cataract [9B10] [11]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Methdilazine and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [12]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Methdilazine and Tiotropium. Chronic obstructive pulmonary disease [CA22] [12]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Methdilazine and Revefenacin. Chronic obstructive pulmonary disease [CA22] [12]
Cyclobenzaprine DM1YBRM Moderate Additive anticholinergic effects by the combination of Methdilazine and Cyclobenzaprine. Depression [6A70-6A7Z] [5]
Selegiline DM6034S Moderate Additive hypotensive effects by the combination of Methdilazine and Selegiline. Depression [6A70-6A7Z] [13]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Methdilazine and Isocarboxazid. Depression [6A70-6A7Z] [13]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Methdilazine and OPC-34712. Depression [6A70-6A7Z] [5]
Clomipramine DMINRKW Moderate Increased plasma concentrations of Methdilazine and Clomipramine due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [10]
Doxepin DMPI98T Moderate Increased plasma concentrations of Methdilazine and Doxepin due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [10]
Maprotiline DMPWB7T Moderate Additive anticholinergic effects by the combination of Methdilazine and Maprotiline. Depression [6A70-6A7Z] [5]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Methdilazine and Esketamine. Depression [6A70-6A7Z] [14]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Methdilazine and Mepenzolate. Digestive system disease [DE2Z] [6]
Oxybutynine DMJPBAX Moderate Additive anticholinergic effects by the combination of Methdilazine and Oxybutynine. Discovery agent [N.A.] [5]
Tetrabenazine DMYWQ0O Major Increased risk of prolong QT interval by the combination of Methdilazine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [15]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Methdilazine and Deutetrabenazine. Dystonic disorder [8A02] [16]
Zonisamide DM0DTF7 Major Additive CNS depression effects by the combination of Methdilazine and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [17]
Diphenhydramine DMKQTBA Moderate Additive anticholinergic effects by the combination of Methdilazine and Diphenhydramine. Episodic vestibular syndrome [AB31] [5]
Ethacrynic acid DM60QMR Moderate Additive hypotensive effects by the combination of Methdilazine and Ethacrynic acid. Essential hypertension [BA00] [18]
Phenoxybenzamine DM8KSQH Moderate Additive hypotensive effects by the combination of Methdilazine and Phenoxybenzamine. Essential hypertension [BA00] [8]
Nadolol DMW6GVL Moderate Additive hypotensive effects by the combination of Methdilazine and Nadolol. Essential hypertension [BA00] [8]
Tolterodine DMSHPW8 Moderate Additive anticholinergic effects by the combination of Methdilazine and Tolterodine. Functional bladder disorder [GC50] [5]
Pilocarpine DMV9ADG Moderate Antagonize the effect of Methdilazine when combined with Pilocarpine. Glaucoma [9C61] [11]
Carvedilol DMHTEAO Moderate Additive hypotensive effects by the combination of Methdilazine and Carvedilol. Heart failure [BD10-BD1Z] [8]
Procarbazine DMIK367 Moderate Additive hypotensive effects by the combination of Methdilazine and Procarbazine. Hodgkin lymphoma [2B30] [13]
Isosorbide mononitrate DMYLMU0 Moderate Additive hypotensive effects by the combination of Methdilazine and Isosorbide mononitrate. Hydrocephalus [8D64] [8]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Methdilazine caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [14]
Acebutolol DM0TI4U Moderate Additive hypotensive effects by the combination of Methdilazine and Acebutolol. Hypertension [BA00-BA04] [8]
Captopril DM458UM Moderate Additive hypotensive effects by the combination of Methdilazine and Captopril. Hypertension [BA00-BA04] [8]
Methyldopa DM5I621 Moderate Additive hypotensive effects by the combination of Methdilazine and Methyldopa. Hypertension [BA00-BA04] [8]
Nebivolol DM7F1PA Moderate Additive hypotensive effects by the combination of Methdilazine and Nebivolol. Hypertension [BA00-BA04] [8]
Levamlodipine DM92S6N Moderate Additive hypotensive effects by the combination of Methdilazine and Levamlodipine. Hypertension [BA00-BA04] [8]
TAK-491 DMCF6SX Moderate Additive hypotensive effects by the combination of Methdilazine and TAK-491. Hypertension [BA00-BA04] [8]
Pindolol DMD2NV7 Moderate Additive hypotensive effects by the combination of Methdilazine and Pindolol. Hypertension [BA00-BA04] [8]
Diazoxide DML1538 Moderate Additive hypotensive effects by the combination of Methdilazine and Diazoxide. Hypertension [BA00-BA04] [8]
Felodipine DMOSW35 Moderate Additive hypotensive effects by the combination of Methdilazine and Felodipine. Hypertension [BA00-BA04] [8]
Irbesartan DMTP1DC Moderate Additive hypotensive effects by the combination of Methdilazine and Irbesartan. Hypertension [BA00-BA04] [8]
Hydralazine DMU8JGH Moderate Additive hypotensive effects by the combination of Methdilazine and Hydralazine. Hypertension [BA00-BA04] [8]
Hydrochlorothiazide DMUSZHD Moderate Additive hypotensive effects by the combination of Methdilazine and Hydrochlorothiazide. Hypertension [BA00-BA04] [8]
Clevidipine butyrate DMW4M97 Moderate Additive hypotensive effects by the combination of Methdilazine and Clevidipine butyrate. Hypertension [BA00-BA04] [8]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Methdilazine and Belladonna. Infectious gastroenteritis/colitis [1A40] [5]
Amantadine DMS3YE9 Moderate Additive anticholinergic effects by the combination of Methdilazine and Amantadine. Influenza [1E30-1E32] [19]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Methdilazine and ITI-007. Insomnia [7A00-7A0Z] [5]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Methdilazine and Polyethylene glycol. Irritable bowel syndrome [DD91] [20]
Physostigmine DM2N0TO Moderate Antagonize the effect of Methdilazine when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [7]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Methdilazine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [21]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Methdilazine and Lasmiditan. Migraine [8A80] [22]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Methdilazine and Flibanserin. Mood disorder [6A60-6E23] [23]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Methdilazine and Thalidomide. Multiple myeloma [2A83] [24]
Ozanimod DMT6AM2 Moderate Additive hypotensive effects by the combination of Methdilazine and Ozanimod. Multiple sclerosis [8A40] [13]
Dextroamphetamine DMMIHVP Moderate Antagonize the effect of Methdilazine when combined with Dextroamphetamine. Narcolepsy [7A20] [9]
Dimenhydrinate DM264B3 Moderate Additive anticholinergic effects by the combination of Methdilazine and Dimenhydrinate. Nausea/vomiting [MD90] [5]
Promethazine DM6I5GR Moderate Additive anticholinergic effects by the combination of Methdilazine and Promethazine. Nausea/vomiting [MD90] [5]
Metoclopramide DMFA5MY Major Additive antidopaminergic effects by the combination of Methdilazine and Metoclopramide. Nausea/vomiting [MD90] [25]
Bupropion DM5PCS7 Major Decreased metabolism of Methdilazine caused by Bupropion mediated inhibition of CYP450 enzyme. Nicotine use disorder [6C4A] [26]
Phendimetrazine DM6TS1N Moderate Antagonize the effect of Methdilazine when combined with Phendimetrazine. Obesity [5B80-5B81] [9]
Amfepramone DM9YSNQ Moderate Antagonize the effect of Methdilazine when combined with Amfepramone. Obesity [5B80-5B81] [9]
Lorcaserin DMG6OYJ Moderate Increased risk of hyperprolactinemic effects by the combination of Methdilazine and Lorcaserin. Obesity [5B80-5B81] [27]
Polythiazide DMCH80F Moderate Additive hypotensive effects by the combination of Methdilazine and Polythiazide. Oedema [MG29] [18]
Lofexidine DM1WXA6 Moderate Additive hypotensive effects by the combination of Methdilazine and Lofexidine. Opioid use disorder [6C43] [8]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Methdilazine and Apraclonidine. Optic nerve disorder [9C40] [28]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Methdilazine and Flavoxate. Pain [MG30-MG3Z] [5]
Methamphetamine DMPM4SK Moderate Antagonize the effect of Methdilazine when combined with Methamphetamine. Pain [MG30-MG3Z] [29]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Methdilazine and Safinamide. Parkinsonism [8A00] [13]
Pergolide DM14MAE Moderate Antagonize the effect of Methdilazine when combined with Pergolide. Parkinsonism [8A00] [30]
Opicapone DM1BKA6 Moderate Antagonize the effect of Methdilazine when combined with Opicapone. Parkinsonism [8A00] [31]
Rasagiline DM3WKQ4 Moderate Additive CNS depression effects by the combination of Methdilazine and Rasagiline. Parkinsonism [8A00] [13]
Levodopa DMN3E57 Moderate Antagonize the effect of Methdilazine when combined with Levodopa. Parkinsonism [8A00] [30]
Bromocriptine DMVE3TK Moderate Antagonize the effect of Methdilazine when combined with Bromocriptine. Parkinsonism [8A00] [30]
Orphenadrine DMW542E Moderate Additive anticholinergic effects by the combination of Methdilazine and Orphenadrine. Parkinsonism [8A00] [5]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Methdilazine and Methylscopolamine. Peptic ulcer [DA61] [5]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Methdilazine caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [32]
Terazosin DM3JCVS Moderate Additive hypotensive effects by the combination of Methdilazine and Terazosin. Prostate hyperplasia [GA90] [8]
Silodosin DMJSBT6 Moderate Additive hypotensive effects by the combination of Methdilazine and Silodosin. Prostate hyperplasia [GA90] [8]
Neupro DMHEAB1 Moderate Antagonize the effect of Methdilazine when combined with Neupro. Restless legs syndrome [7A80] [30]
Quetiapine DM1N62C Moderate Additive anticholinergic effects by the combination of Methdilazine and Quetiapine. Schizophrenia [6A20] [5]
Mesoridazine DM2ZGAN Moderate Additive anticholinergic effects by the combination of Methdilazine and Mesoridazine. Schizophrenia [6A20] [6]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Methdilazine and Aripiprazole. Schizophrenia [6A20] [5]
Iloperidone DM6AUFY Moderate Additive anticholinergic effects by the combination of Methdilazine and Iloperidone. Schizophrenia [6A20] [5]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Methdilazine and Molindone. Schizophrenia [6A20] [5]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Methdilazine and Thiothixene. Schizophrenia [6A20] [5]
Asenapine DMSQZE2 Moderate Additive anticholinergic effects by the combination of Methdilazine and Asenapine. Schizophrenia [6A20] [5]
Pimozide DMW83TP Moderate Additive anticholinergic effects by the combination of Methdilazine and Pimozide. Schizophrenia [6A20] [5]
Papaverine DMCA9QP Moderate Additive hypotensive effects by the combination of Methdilazine and Papaverine. Tonus and reflex abnormality [MB47] [8]
⏷ Show the Full List of 94 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7231).
2 Methdilazine FDA Label
3 Effect of H1 blockers alone and in combination with morphine to produce antinociception in mice. Neuropharmacology. 1985 Jan;24(1):1-4.
4 Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.
5 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
6 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
7 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
8 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
9 Achor MB, Extein I "Diet aids, mania, and affective illness" Am J Psychiatry 138 (1981): 392. [PMID: 7468847]
10 Bock JL, Nelson JC, Gray S, Jatlow PI "Desipramine hydroxylation: variability and effect of antipsychotic drugs." Clin Pharmacol Ther 33 (1983): 322-8. [PMID: 6130865]
11 Multum Information Services, Inc. Expert Review Panel.
12 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
13 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
14 Cerner Multum, Inc. "Australian Product Information.".
15 Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH "Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease." Neurology 31 (1981): 1022-5. [PMID: 6115336]
16 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
17 Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
18 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
19 Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
20 Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
21 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
22 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
23 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
24 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
25 Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985): 930-2. [PMID: 3929968]
26 Canadian Pharmacists Association.
27 Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
28 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
29 Lake CR "Manic psychosis after coffee and phenylpropanolamine." Biol Psychiatry 30 (1991): 401-4. [PMID: 1912131]
30 Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
31 Product Information. Norprolac (quinagolide). Ferring Inc, North York, IA.
32 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.